Luxury Empire LVMH's Hold on Europe's No.1 Market Cap Is at Risk

Danish pharmaceutical company Novo Nordisk has recently seen its market capitalization surge due to a sharp rise in its stock price, putting it in contention for the top spot in European stock market capitalization, currently held by LVMH Mo?t Hennessy (LVMH).

According to Bloomberg on the 8th (local time), Novo Nordisk, listed on the Danish stock exchange, had a market capitalization of $423 billion on that day, closely trailing LVMH's $442 billion, the largest in the European stock market.

On the same day, Novo Nordisk's stock price rose 17.26% from the previous close to 1,279.80 kroner, marking an all-time high closing price. The surge was driven by positive research results showing that the obesity treatment drug 'Wegovy' not only treats obesity but also reduces the risk of cardiovascular diseases.

During the trading session, Novo Nordisk announced its own research results from a clinical trial involving 17,604 adults aged 45 and older who were overweight and had cardiovascular disease, conducted over up to five years. The study showed that Wegovy reduced the risk of heart attack, stroke, and cardiovascular death by 20%.

Wegovy, also known as Elon Musk Tesla CEO's obesity injection, has driven a rapid increase in sales, propelling the company's stock price to soar over the past three years. Bloomberg reported, "Thanks to obesity treatments including Wegovy, Novo Nordisk's stock price has tripled since the end of 2020, surpassing other European mega-caps such as Nestl? and ASML."

[Image source=Reuters Yonhap News]

This year, the stock price has risen by 36%, roughly double LVMH's 18% increase. LVMH, benefiting from expectations of economic reopening in China, the largest consumer of luxury goods, saw its stock price surge and became the first European company to surpass a $500 billion market cap in April. However, it has recently experienced a downward trend due to earnings falling short of expectations.

Founded in Denmark in 1923, Novo Nordisk holds over 50% market share in the obesity treatment market and more than 30% in the diabetes market. Sales from the obesity and diabetes segments account for approximately 88% of total revenue.

This content was produced with the assistance of AI translation services.